Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;12(7):1028-1030.
doi: 10.1002/mdc3.70060. Epub 2025 Mar 28.

Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease

Affiliations

Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease

Sacha Brohée et al. Mov Disord Clin Pract. 2025 Jul.
No abstract available

Keywords: Parkinson's disease; confusion; delirium; foslevodopa; hallucinations.

PubMed Disclaimer

References

    1. Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa‐foscarbidopa in patients with advanced Parkinson's disease: a randomised, double‐blind, active‐controlled, phase 3 trial. Lancet Neurol 2022;21(12):1099–1109. 10.1016/S1474-4422(22)00400-8. - DOI - PubMed
    1. Nukariya T, Tezuka T, Okusa S, Okochi R, Sakai Y, Nihei Y, et al. Levodopa pharmacokinetics in switching from levodopa/carbidopa intestinal gel to continuous subcutaneous Foslevodopa/Foscarbidopa infusion in a patient with Parkinson's disease: a case report. J Mov Disord 2025. 10.14802/jmd.24247. - DOI - PMC - PubMed
    1. Fung VSC, Aldred J, Arroyo MP, et al. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: considerations for initiation and maintenance. Clin Park Relat Disord 2024;10:100239. - PMC - PubMed

LinkOut - more resources